JP7024091B2 - キナーゼ阻害剤としてのアミノ－メチルピペリジン誘導体 - Google Patents

キナーゼ阻害剤としてのアミノ－メチルピペリジン誘導体 Download PDF

Info

Publication number
JP7024091B2
JP7024091B2 JP2020534937A JP2020534937A JP7024091B2 JP 7024091 B2 JP7024091 B2 JP 7024091B2 JP 2020534937 A JP2020534937 A JP 2020534937A JP 2020534937 A JP2020534937 A JP 2020534937A JP 7024091 B2 JP7024091 B2 JP 7024091B2
Authority
JP
Japan
Prior art keywords
amino
pyrazole
pyrrolo
pyrimidin
methylpiperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020534937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507923A (ja
Inventor
キム，インウ
キム，ナムヨン
チョン，スンファン
キム，ボギョン
イ，ジュンヒ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of JP2021507923A publication Critical patent/JP2021507923A/ja
Application granted granted Critical
Publication of JP7024091B2 publication Critical patent/JP7024091B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
JP2020534937A 2017-12-28 2018-12-28 キナーゼ阻害剤としてのアミノ－メチルピペリジン誘導体 Active JP7024091B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0183062 2017-12-28
KR1020170183062A KR102577242B1 (ko) 2017-12-28 2017-12-28 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
PCT/KR2018/016813 WO2019132561A1 (ko) 2017-12-28 2018-12-28 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체

Publications (2)

Publication Number Publication Date
JP2021507923A JP2021507923A (ja) 2021-02-25
JP7024091B2 true JP7024091B2 (ja) 2022-02-22

Family

ID=67067897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534937A Active JP7024091B2 (ja) 2017-12-28 2018-12-28 キナーゼ阻害剤としてのアミノ－メチルピペリジン誘導体

Country Status (23)

Country Link
US (1) US11407754B2 (ru)
EP (1) EP3733674B1 (ru)
JP (1) JP7024091B2 (ru)
KR (1) KR102577242B1 (ru)
CN (1) CN111527088B (ru)
AU (1) AU2018394996B2 (ru)
BR (1) BR112020013237A2 (ru)
CA (1) CA3085160C (ru)
CL (1) CL2020001749A1 (ru)
CO (1) CO2020007156A2 (ru)
DO (1) DOP2020000111A (ru)
EC (1) ECSP20035588A (ru)
ES (1) ES2924225T3 (ru)
MA (1) MA51433A (ru)
MX (1) MX2020006798A (ru)
MY (1) MY196572A (ru)
NZ (1) NZ765152A (ru)
PE (1) PE20210549A1 (ru)
RU (1) RU2756505C1 (ru)
SA (1) SA520412334B1 (ru)
SG (1) SG11202004916YA (ru)
TN (1) TN2020000081A1 (ru)
WO (1) WO2019132561A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200629A (en) 2017-08-01 2024-01-06 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
RS63515B1 (sr) 2017-12-28 2022-09-30 Daewoong Pharmaceutical Co Ltd Derivat oksi-fluoropiperidina kao inhibitor kinaze
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-***并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
KR102228668B1 (ko) * 2019-10-08 2021-03-17 (주)부흥산업사 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
CN112824381B (zh) * 2019-11-21 2024-04-26 广东东阳光药业股份有限公司 一种哌啶胺的制备方法
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
CN115244055A (zh) * 2020-01-21 2022-10-25 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
CN113214265B (zh) * 2020-01-21 2023-07-07 江苏先声药业有限公司 嘧啶并五元环类化合物
WO2021147952A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并吡咯类化合物
TW202214643A (zh) * 2020-09-22 2022-04-16 大陸商江蘇先聲藥業有限公司 嘧啶并吡咯類化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526113A (ja) 2009-05-05 2012-10-25 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
JP2013529630A (ja) 2010-06-23 2013-07-22 ハンミ・サイエンス・カンパニー・リミテッド チロシンキナーゼ活性阻害作用を有する新規な縮合ピリミジン誘導体
JP2014526549A (ja) 2011-09-22 2014-10-06 ファイザー・インク ピロロピリミジンおよびプリン誘導体
JP2015524468A (ja) 2012-08-06 2015-08-24 エイシア バイオサイエンシーズ インコーポレイテッド プロテインキナーゼの阻害剤としての新規ピロロピリミジン化合物
CN105732637A (zh) 2014-12-30 2016-07-06 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP2016530335A (ja) 2013-09-18 2016-09-29 北京韓美薬品有限公司 Ｂｔｋ及び／又はｊａｋ３キナーゼの活性を抑制する化合物
JP2016539137A (ja) 2013-12-05 2016-12-15 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
WO2017106771A1 (en) 2015-12-16 2017-06-22 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
JP2019519579A (ja) 2016-06-30 2019-07-11 デウン ファーマシューティカル カンパニー リミテッド キナーゼ阻害剤としてのピラゾロピリミジン誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
ES2718206T3 (es) 2012-11-08 2019-06-28 Compac Tech Limited Soporte de artículos para un aparato de clasificación
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
CN106432294B (zh) 2016-09-19 2018-01-30 淮北师范大学 发光配合物及其制备方法
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
RS63515B1 (sr) 2017-12-28 2022-09-30 Daewoong Pharmaceutical Co Ltd Derivat oksi-fluoropiperidina kao inhibitor kinaze
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526113A (ja) 2009-05-05 2012-10-25 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
JP2013529630A (ja) 2010-06-23 2013-07-22 ハンミ・サイエンス・カンパニー・リミテッド チロシンキナーゼ活性阻害作用を有する新規な縮合ピリミジン誘導体
JP2014526549A (ja) 2011-09-22 2014-10-06 ファイザー・インク ピロロピリミジンおよびプリン誘導体
JP2015524468A (ja) 2012-08-06 2015-08-24 エイシア バイオサイエンシーズ インコーポレイテッド プロテインキナーゼの阻害剤としての新規ピロロピリミジン化合物
JP2016530335A (ja) 2013-09-18 2016-09-29 北京韓美薬品有限公司 Ｂｔｋ及び／又はｊａｋ３キナーゼの活性を抑制する化合物
JP2016539137A (ja) 2013-12-05 2016-12-15 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
CN105732637A (zh) 2014-12-30 2016-07-06 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2017106771A1 (en) 2015-12-16 2017-06-22 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
JP2019519579A (ja) 2016-06-30 2019-07-11 デウン ファーマシューティカル カンパニー リミテッド キナーゼ阻害剤としてのピラゾロピリミジン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Simon Planken et al.，Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide(PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR，Journal of Medicinal Chemistry，2017年，vol.60, no.7，pp.3002-3019
Wenjun Zhou et al.，Discovery of selective irreversible inhibitors for EGFR-T790M，Bioorganic & Medicinal Chemistry Letters，vol.21, no.2，2011年，pp.638-643

Also Published As

Publication number Publication date
CN111527088A (zh) 2020-08-11
US20210188854A1 (en) 2021-06-24
EP3733674A1 (en) 2020-11-04
MA51433A (fr) 2021-04-07
TN2020000081A1 (en) 2022-01-06
CA3085160C (en) 2021-12-07
PE20210549A1 (es) 2021-03-17
MX2020006798A (es) 2020-09-03
NZ765152A (en) 2024-02-23
SG11202004916YA (en) 2020-06-29
CO2020007156A2 (es) 2020-06-19
AU2018394996A2 (en) 2020-07-16
WO2019132561A1 (ko) 2019-07-04
AU2018394996A1 (en) 2020-06-25
US11407754B2 (en) 2022-08-09
SA520412334B1 (ar) 2022-11-03
AU2018394996B2 (en) 2021-08-05
KR102577242B1 (ko) 2023-09-11
DOP2020000111A (es) 2020-09-30
EP3733674B1 (en) 2022-06-29
CN111527088B (zh) 2022-12-30
KR20190080541A (ko) 2019-07-08
EP3733674A4 (en) 2021-06-09
WO2019132561A8 (ko) 2020-06-11
MY196572A (en) 2023-04-19
CL2020001749A1 (es) 2020-11-06
ES2924225T3 (es) 2022-10-05
CA3085160A1 (en) 2019-07-04
ECSP20035588A (es) 2020-07-31
JP2021507923A (ja) 2021-02-25
BR112020013237A2 (pt) 2020-12-01
RU2756505C1 (ru) 2021-10-01

Similar Documents

Publication Publication Date Title
JP7024091B2 (ja) キナーゼ阻害剤としてのアミノ－メチルピペリジン誘導体
JP7032535B2 (ja) キナーゼ阻害剤としてのアミノ－フルオロピペリジン誘導体
JP6995428B2 (ja) キナーゼ阻害剤としてのオキシ－フルオロピペリジン誘導体
JP2020143162A (ja) キナーゼ阻害剤としてのピラゾロピリミジン誘導体
NZ765159B2 (en) Amino-fluoropiperidine derivative as kinase inhibitor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220209

R150 Certificate of patent or registration of utility model

Ref document number: 7024091

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150